D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
for
Newly Diagnosed MGMT Unmethylated Glioblastoma
Location: Durham NC
Sponsor: Darell Bigner
Sex: All
Age: 18+
Code: NCT05734560
Phase1, Phase2, Recruiting
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
for
Newly Diagnosed Glioblastoma
Location: New York NY, Durham NC, Houston TX
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06816927
Phase2, Recruiting
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
for
Recurrent Glioblastoma, IDH-Wildtype,
Location: Jacksonville FL
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT05789394
Phase1, Recruiting
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
for
Glioma, Glioblastoma, Brain Tumor
Location: Bel Air MD, Glen Burnie MD, Baltimore MD, Columbia MD
Sponsor: University of Maryland, Baltimore
Sex: All
Age: 18+
Code: NCT04699773
Recruiting
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
for
Glioblastoma, IDH-wildtype, Glioblastoma,
Location: Boston MA, San Francisco CA
Sponsor: Erasmus Medical Center
Sex: All
Age: 0 - 70+
Code: NCT06273176
Recruiting
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
for
Recurrent Astrocytoma, IDH-Mutant, Grade 3,
Location: Duarte CA
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT06815029
Phase1, Recruiting
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
for
Glioblastoma
Location: Boston MA, New York NY, Pittsburgh PA
Sponsor: David Reardon, MD
Sex: All
Age: 18+
Code: NCT02977780
Phase2, Recruiting
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
for
Glioblastoma, Glioblastoma Multiforme
Location: St Louis MO
Sponsor: Washington University School of Medicine
Sex: All
Age: 18+
Code: NCT05281731
Recruiting
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
for
Currently Only Enrolling Glioblastoma Patients at First Recurrence,